Consumer confidence leads to H2 warning for Visx:
This article was originally published in Clinica
Laser vision correction company Visx has warned of lower revenues and profits for the second half of the year, due to weak consumer confidence - a major driver of demand for its technology. The Santa Clara, California-based company is expecting second-half EPS of $0.15-0.18, compared with consensus figure of $0.26. For the second quarter, the company had sales of $37m, the same as for the first quarter, but down from the $48m of the previous year's second quarter.
You may also be interested in...
Italy Round-Up: Mylan And Polifarma Strike Deal, OTC Market Stable, Cholesterol-Lowering Probiotic Launch
The latest news from Italy's OTC and supplements markets, including the latest sales figures, business deals, product launches, ad regulation and local association activities.
Sandoz CEO Richard Saynor has pledged that the company will ensure stable pricing for essential coronavirus-related medicines amid concerns over how the outbreak will affect the supply chain.
Executives On The Move: Comings And Goings At Atara Biothera And Pfizer, Along With A Promotion At Domainex
T-cell immunotherapy firm Atara Biotherapeutics decides on a chief commercial officer and Pfizer oncology R&D head leaves for CSO spot at Vividion Therapeutics. Also, COO of UK drug discovery CRO Domainex is set to climb to CEO position.